- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04262856
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open-label phase 2 study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutics across multiple treatment arms.
Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab, 2) zimberelimab + domvanalimab (anti-TIGIT antibody), 3) zimberelimab + domvanalimab + etrumadenant (dual adenosine receptor antagonist). Participants that progress on the zimberelimab monotherapy arm may cross-over to receive the third arm combination of zimberelimab + domvanalimab + etrumadenant.
The primary objective of this clinical study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Border Medical Oncology
-
Coffs Harbour, New South Wales, Australia, 2450
- Coffs Harbour Health Campus
-
Nowra, New South Wales, Australia, 2500
- Shoalhaven Cancer Care Centre
-
Tweed Heads, New South Wales, Australia, 2485
- Tweed Hospital
-
-
South Australia
-
Elizabeth Vale, South Australia, Australia, 5112
- Adelaide Cancer Centre
-
-
-
-
-
Brampton, Canada, L6R 3J7
- Brampton Civic Hospital (Bch), William Osler Health Centre
-
Montréal, Canada, H4A 3J1
- McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)
-
Saint Jerome, Canada, J7Z 5T3
- Centre Integre de Sante et de Services Sociaux des Laurentides Hopital regional de Saint-Jerome
-
-
-
-
-
Hong Kong, Hong Kong
- Princess Margaret Hospital
-
Hong Kong, Hong Kong
- Hong Kong United Oncology Centre
-
Hong Kong, Hong Kong
- Humanity and Health Research Center
-
Hong Kong, Hong Kong
- Queen Elizabeth Hospital (Hong Kong)
-
-
-
-
-
Busan, Korea, Republic of, 49267
- Kosin University Gospel Hospital
-
Hwasun, Korea, Republic of, 58128
- Chonnam University Hospital
-
Incheon, Korea, Republic of, 21565
- Gachon University Gil Medical Center
-
Jeonju, Korea, Republic of, 54907
- Chonbuk National University Hospital
-
Seongnam-si, Korea, Republic of, 13620
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of, 02841
- Korea University Anam Hospital
-
Seoul, Korea, Republic of, 5505
- Asan Medical Center
-
Seoul, Korea, Republic of, 03181
- Kangbuk Samsung Hospital
-
Seoul, Korea, Republic of, 2841
- Korea University Anam Hospital
-
Suwon-si, Korea, Republic of, 16247
- St Vincent Hospital of the Catholic University of Korea
-
Uijeongbu, Korea, Republic of, 11765
- Catholic University of Korea, Uijeongbu St. Mary's Hospital
-
-
-
-
-
Singapore, Singapore, 188770
- Raffles Hospital
-
Singapore, Singapore, 258499
- Oncocare Cancer Centre
-
Singapore, Singapore, 329563
- Curie Oncology
-
-
-
-
-
Kaohsiung, Taiwan
- Chang Gung Memorial Hospital
-
Kaohsiung City, Taiwan, 83301
- Chang gung memorial hospital, Kaohsiung branch
-
New Taipei, Taiwan, 23561
- Taipei Medical University - Shuang Ho Hospital
-
Taichung City, Taiwan, 40201
- Chung Shan Medical University Hospital
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital
-
Tainan City, Taiwan, 736
- Chi Mei Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
Taipei, Taiwan, 110
- Taipei Medical University Hospital
-
Taipei City, Taiwan, 114
- Tri-Service General Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital at Linkou
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
California
-
Anaheim, California, United States, 92801
- Pacific Cancer Medical Center, Inc
-
Whittier, California, United States, 90603
- Innovative Clinical Research Institute (ICRI)
-
-
Florida
-
Englewood, Florida, United States, 34223
- Florida Cancer Specialists
-
Gainesville, Florida, United States, 32605
- Florida Cancer Specialists
-
Saint Petersburg, Florida, United States, 33705
- Florida Cancer Specialists
-
Tallahassee, Florida, United States, 32308
- Florida Cancer Specialists - Panhandle
-
West Palm Beach, Florida, United States, 33401
- Florida Cancer Specialists - East
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute
-
Louisville, Kentucky, United States, 40207
- Baptist Hospital East
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- American Oncology Partners of Maryland, PA
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Detroit Clinical Research Center, PC
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Hattiesburg Clinic
-
-
Nevada
-
Las Vegas, Nevada, United States, 89196
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Ridgewood, New Jersey, United States, 07450
- The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion
-
-
New York
-
Lake Success, New York, United States, 11042
- Clinical Research Alliance
-
Lake Success, New York, United States, 11042
- Northwell Health Cancer Institute
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest Baptist Health
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15224
- Allegheny General Hospital (AGH)-Alleghney Singer Research Institute
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Prisma Health-Upstate
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Sarah Cannon Research Institute
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- The Center For Cancer And Blood Disorders (Texas Cancer Care)
-
Kingwood, Texas, United States, 77339
- Dr.John R Waldron, MD Off of
-
Lubbock, Texas, United States, 79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler, Texas, United States, 75701
- Tyler Hematology-Oncology, P.A.
-
-
Virginia
-
Blacksburg, Virginia, United States, 24060
- Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female participants; age ≥ 18 years
- Histologically confirmed, treatment naïve, metastatic squamous or non-squamous NSCLC with documented high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Must have at least 1 measurable lesion per RECIST v1.1
- Adequate organ and marrow function
Exclusion Criteria:
- Use of any live vaccines against infectious diseases within 28 days of first dose of investigational medicinal products (IMPs)
- Any gastrointestinal condition that would preclude the use of oral medications (eg, difficulty swallowing, nausea, vomiting, or malabsorption)
- History of trauma or major surgery within 28 days prior to the first dose of IMP
- Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications
- Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody with presence of Hepatitis C qualitative RNA or human immunodeficiency virus (HIV-1 and/or HIV-2) antibody at screening
- Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
- Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 (zimberelimab monotherapy)
Participants will receive zimberelimab as an intravenous (IV) infusion.
|
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
|
Experimental: Arm 2 (domvanalimab and zimberelimab combination therapy)
Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
|
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
|
Experimental: Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)
Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
|
Etrumadenant is an A2aR and A2bR antagonist
Other Names:
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: From randomization until death from any cause (up to approximately 3-5 years)
|
ORR as assessed by RECIST v1.1
|
From randomization until death from any cause (up to approximately 3-5 years)
|
Progression-free survival (PFS)
Time Frame: From randomization until death from any cause (up to approximately 3-5 years)
|
PFS as assessed by RECIST v1.1
|
From randomization until death from any cause (up to approximately 3-5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DoR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
DoR as assessed by RECIST v1.1
|
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
Disease control rate (DCR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression on death from any cause, whichever occurs first (up to approximately 3-5 years)
|
DCR as assessed by RECIST v1.1
|
From the date of first occurrence of a documented objective response to first documentation of disease progression on death from any cause, whichever occurs first (up to approximately 3-5 years)
|
Overall Survival (OS)
Time Frame: From randomization to death from any cause (up to approximately 5 years)
|
OS as assessed at the time of PFS
|
From randomization to death from any cause (up to approximately 5 years)
|
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time Frame: From Screening until up to 30 days after the last dose (approximately 5 years)
|
The number and percentage of participants that experience TEAE
|
From Screening until up to 30 days after the last dose (approximately 5 years)
|
Pharmacokinetics of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of zimberelimab as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Pharmacokinetics of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of domvanalimab as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Pharmacokinetics of etrumadenant
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Serum concentration of etrumadenant as determined by validated assays
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
|
Immunogenicity of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Immunogenicity of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab
|
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Arcus Biosciences, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARC-7 (AB154CSP0002)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Etrumadenant
-
Arcus Biosciences, Inc.Gilead SciencesCompletedHealthy ParticipantsUnited States
-
Washington University School of MedicineArcus Biosciences, Inc.Active, not recruitingNon Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell CarcinomaUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
Arcus Biosciences, Inc.CompletedColorectal Cancer | GastroEsophageal CancerUnited States, Australia
-
Arcus Biosciences, Inc.CompletedMelanoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer | Merkel Cell Carcinoma | GastroEsophageal CancerUnited States, Australia
-
Memorial Sloan Kettering Cancer CenterRecruitingSarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated LiposarcomaUnited States
-
Surface OncologyArcus Biosciences, Inc.CompletedProstate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Jennifer ChoeArcus Biosciences, Inc.WithdrawnHead and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Oropharynx Cancer | Oral Cavity Cancer | Oropharynx Squamous Cell Carcinoma | Pharynx Cancer | Larynx Cancer | Hypopharynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell CarcinomaUnited States
-
Weill Medical College of Cornell UniversityArcus Biosciences, Inc.Recruiting
-
Ono Pharma USA IncCompletedMultiple SclerosisUnited States, Belgium, Canada, Czech Republic, Germany, Greece, Japan, Poland, Russian Federation, Spain, Ukraine